Skip to main content

Advertisement

Table 3 Final Cox proportional odds regression model

From: Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis

Variable B SE Wald p Hazard ratio 95,0% CI for Exp(B)
       Lower Upper
PS(60 vs ≤ 50) ,376 ,268 1,966 ,161 1,456 ,861 2,461
PS(70 vs ≤ 50) -,501 ,319 2,467 ,116 ,606 ,324 1,132
PS(80 vs ≤ 50) -1,180 ,345 11,676 ,001 ,307 ,156 ,605
PS(90 vs ≤ 50) -1,357 ,420 10,437 ,001 ,257 ,113 ,586
PRIMARY EXTENT(4 vs 1) ,085 ,489 ,030 ,862 1,088 ,418 2,836
PRIMARY EXTENT (3 vs 1) ,399 ,495 ,649 ,420 1,491 ,564 3,936
PRIMARY EXTENT (2 vs 1) 1,015 ,518 3,838 ,050 2,758 1,000 7,610
DISTANT METASTASES (yes vs no) ,949 ,247 14,730 ,000 2,583 1,591 4,194
PLOIDY (3.6+ vs <2.2) 1,605 ,341 22,093 ,000 4,975 2,548 9,714
PLOIDY (2.2–3.6 vs <2.2) 1,846 ,375 24,251 ,000 6,333 3,038 13,201
EPOETIN – ANEMIA (yes vs no) -,441 ,184 5,779 ,016 ,643 ,449 ,922
WEIGHT LOSS (none vs 10+) -,536 ,379 1,997 ,158 ,585 ,278 1,230
WEIGHT LOSS (1–5% vs 10+) -1,081 ,330 10,719 ,001 ,339 ,178 ,648
WEIGHT LOSS (5–10% vs10+) -1,097 ,268 16,756 ,000 ,334 ,197 ,565
PAIN (none vs severe) -,360 ,355 1,028 ,311 ,698 ,348 1,399
PAIN (light vs severe) -,224 ,286 ,613 ,434 ,799 ,456 1,400
PAIN (moderate vs severe) -,769 ,281 7,486 ,006 ,463 ,267 ,804
STEATORIA (yes vs no) ,585 ,183 10,185 ,001 1,795 1,253 2,572
CEA (>5 vs <= 5) ,345 ,161 4,586 ,032 1,413 1,030 1,938
THERAPY (CT vs none) -1,449 ,272 28,445 ,000 ,235 ,138 ,400
THERAPY (Surgery vs none) -,416 ,254 2,669 ,102 ,660 ,401 1,087
THERAPY(both vs none) -1,903 ,270 49,641 ,000 ,149 ,088 ,253
  1. PS, Performance Status; CEA, carcinoembryonic antigen; CT, Chemotherapy.